Ganglioside GM3 (GM3) (GM3)

Ganglioside GM3 is a fundamental glycosphingolipid found on the surface of mammalian cells, composed of a ceramide tail and a carbohydrate headgroup containing one sialic acid residue (Source: PubChem CID 11230). It serves as a key component of lipid rafts, where it regulates the activity of various transmembrane signaling proteins, most notably the epidermal growth factor receptor (EGFR) and the insulin receptor (Source: PMID: 22531443). In oncology, an altered form known as N-glycolyl GM3 (NeuGcGM3) is highly expressed in several solid tumors but is virtually absent in normal human tissues, making it an attractive target for immunotherapy (Source: PMID: 30111533). Therapeutic strategies include the use of anti-idiotypic antibodies like racotumomab and monoclonal antibodies designed to induce tumor cell death and stimulate an immune response (Source: PMID: 24103114). Beyond cancer, GM3 is implicated in the pathogenesis of type 2 diabetes, where its accumulation in cell membranes can inhibit insulin signaling, leading to insulin resistance (Source: PMID: 22531443). It also plays roles in cell-cell recognition, adhesion, and the regulation of apoptosis. Mutations in the enzymes responsible for GM3 synthesis, such as ST3GAL5, can lead to severe neurodevelopmental disorders like GM3 synthase deficiency (Source: NIH/GARD).

Other names

MonosialodihexosylgangliosideHematosideNeu5Ac-alpha-2,3-Gal-beta-1,4-Glc-beta-1-CeramideN-AcetylneuraminylgalactosylglucosylceramideII3NeuAc-LacCer

Induction of antibody-dependent cellular cytotoxicity (ADCC), inhibition of receptor tyrosine kinase signaling (e.g., EGFR and insulin receptor), and stimulation of an anti-tumor immune response through anti-idiotypic mimicry.